News

Filter

Current filters:

Dysport

1 to 9 of 50 results

Ipsen's Dysport gives positive results in adult and pediatric lower limb spasticity

Ipsen's Dysport gives positive results in adult and pediatric lower limb spasticity

26-01-2015

French drugmaker Ipsen has announced top line results from two double-blind Phase III trials of Dysport…

CNS DiseasesDysportFranceIpsenPharmaceuticalResearch

Ipsen’s Dysport accepted for review by US FDA

Ipsen’s Dysport accepted for review by US FDA

28-11-2014

French drugmaker Ipsen says that the US Food and Drug Administration has accepted for review its supplemental…

DysportIpsenNeurologicalPharmaceuticalRegulationUSA

Specialty care and Somatuline drive Ipsen's positive third quarter financials

Specialty care and Somatuline drive Ipsen's positive third quarter financials

29-10-2014

French drugmaker Ipsen has reported sales of 329 million euros ($419.1 million) for the third quarter…

DysportFinancialFranceIpsenPharmaceuticalSomatuline

Ipsen sales up in first quarter, boosted by specialty care

Ipsen sales up in first quarter, boosted by specialty care

30-04-2014

French drugmaker Ipsen has reported sales of 305.9 million euros ($423 million) for the first quarter…

Business FinanceBusiness FinanceDecapeptylDysportEURFinancialFranceIpsenPfizerPharmaceuticalSomatulineTriptorelin

Ipsen’s Dysport next generation shows safety and efficacy in Phase III

Ipsen’s Dysport next generation shows safety and efficacy in Phase III

05-02-2014

French drugmaker Ipsen today announced the results of the international Phase III clinical trial of Dysport…

DysportFranceGeneticsIpsenPharmaceuticalResearch

Ipsen reports positive Phase III results for Dysport in adult upper limb spasticity

Ipsen reports positive Phase III results for Dysport in adult upper limb spasticity

17-12-2013

French drugmaker Ipsen (Euronext: IPN) has announced positive initial results from a Phase III study…

DysportIpsenNeurologicalNorthern EuropePharmaceuticalResearch

News briefs on Ipsen/Galderma and YM BioSciences nimotuzumab assets

04-12-2012

French drugmaker Ipsen (Euronext: IPN) and Switzerland-headquartered Galderma have expanded their collaboration…

Asia-PacificBiotechnologyCIMABDysportGaldermaInnoKeys PTEIpsenLicensingnimotuzumabOncologyPharmaceuticalSouth AmericaYM Biosciences

1 to 9 of 50 results

COMPANY SPOTLIGHT

Menarini

Back to top